CO2023016081A2 - Composición farmacéutica para prevenir o tratar una enfermedad cerebral y alimento funcional de salud para prevenir o aliviar una enfermedad cerebral que la comprende - Google Patents
Composición farmacéutica para prevenir o tratar una enfermedad cerebral y alimento funcional de salud para prevenir o aliviar una enfermedad cerebral que la comprendeInfo
- Publication number
- CO2023016081A2 CO2023016081A2 CONC2023/0016081A CO2023016081A CO2023016081A2 CO 2023016081 A2 CO2023016081 A2 CO 2023016081A2 CO 2023016081 A CO2023016081 A CO 2023016081A CO 2023016081 A2 CO2023016081 A2 CO 2023016081A2
- Authority
- CO
- Colombia
- Prior art keywords
- preventing
- brain disease
- asm
- alleviating
- inhibiting
- Prior art date
Links
- 208000014644 Brain disease Diseases 0.000 title abstract 3
- 235000013402 health food Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 abstract 5
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se revela el uso de un anticuerpo o fragmento de unión antígeno del mismo que se une específicamente a una proteína del ácido esfingomielinasa (ASM), donde el anticuerpo o fragmento de unión antígeno del mismo se une específicamente a una proteína ASM con alta afinidad, inhibe significantemente la actividad de la proteína ASM presente en la membrana celular y muestra efectos de mejora de la memoria cognitiva, inhibiendo la actividad de la proteína ASM, inhibiendo la acumulación de proteínas amiloide-β y tau e inhibiendo la producción de neuroinflamación aún sin toxicidad en modelos animales con enfermedad de Alzheimer, y así puede usarse ventajosamente en el tratamiento de una enfermedad cerebral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210068628 | 2021-05-27 | ||
| KR1020220057049A KR20220160483A (ko) | 2021-05-27 | 2022-05-10 | Asm 단백질에 특이적으로 결합하는 항체를 유효성분으로 포함하는 뇌질환 치료용 약학적 조성물 |
| PCT/KR2022/007485 WO2022250470A1 (ko) | 2021-05-27 | 2022-05-26 | Asm 단백질에 특이적으로 결합하는 항체를 유효성분으로 포함하는 뇌질환 치료용 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023016081A2 true CO2023016081A2 (es) | 2023-12-11 |
Family
ID=84228972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0016081A CO2023016081A2 (es) | 2021-05-27 | 2023-11-23 | Composición farmacéutica para prevenir o tratar una enfermedad cerebral y alimento funcional de salud para prevenir o aliviar una enfermedad cerebral que la comprende |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4349865A1 (es) |
| JP (1) | JP7484028B1 (es) |
| AR (1) | AR126038A1 (es) |
| AU (1) | AU2022279866A1 (es) |
| BR (1) | BR112023024632A2 (es) |
| CA (1) | CA3219114A1 (es) |
| CO (1) | CO2023016081A2 (es) |
| IL (1) | IL308738A (es) |
| WO (1) | WO2022250470A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11242529B2 (en) | 2013-05-07 | 2022-02-08 | Kyungpook National University Industry-Academic Cooperation Foundation | Method for treating a neurological disorder comprising administering ASM inhibitors |
| KR101521117B1 (ko) | 2013-05-07 | 2015-05-18 | 경북대학교 산학협력단 | Ａｓｍ 억제제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
-
2022
- 2022-05-26 IL IL308738A patent/IL308738A/en unknown
- 2022-05-26 WO PCT/KR2022/007485 patent/WO2022250470A1/ko active Application Filing
- 2022-05-26 JP JP2023572865A patent/JP7484028B1/ja active Active
- 2022-05-26 EP EP22811661.2A patent/EP4349865A1/en active Pending
- 2022-05-26 BR BR112023024632A patent/BR112023024632A2/pt unknown
- 2022-05-26 AR ARP220101397A patent/AR126038A1/es unknown
- 2022-05-26 AU AU2022279866A patent/AU2022279866A1/en active Pending
- 2022-05-26 CA CA3219114A patent/CA3219114A1/en active Pending
-
2023
- 2023-11-23 CO CONC2023/0016081A patent/CO2023016081A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3219114A1 (en) | 2022-12-01 |
| AR126038A1 (es) | 2023-09-06 |
| JP7484028B1 (ja) | 2024-05-15 |
| JP2024521163A (ja) | 2024-05-28 |
| TW202246355A (zh) | 2022-12-01 |
| IL308738A (en) | 2024-01-01 |
| WO2022250470A1 (ko) | 2022-12-01 |
| BR112023024632A2 (pt) | 2024-02-27 |
| EP4349865A1 (en) | 2024-04-10 |
| AU2022279866A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Afrin et al. | Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases | |
| Garwood et al. | Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture | |
| EA200800050A1 (ru) | Самобуферирующиеся композиции белков | |
| BR112013017446A2 (pt) | composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona | |
| Bloom et al. | MIF: mood improving/inhibiting factor? | |
| BR112014016887A2 (pt) | potencialização do transporte de moléculas terapêu-ticas através da barreira hematoencefálica | |
| Rudd et al. | The involvement of TRPV1 in emesis and anti-emesis | |
| MA41150A (fr) | Polymères de liaison aux protons pour administration orale | |
| BR112022021823A2 (pt) | Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria | |
| Coeytaux et al. | Evidence Map of Yoga for High-Impact Conditions Affecting Veterans [Internet] | |
| BR112023005207A2 (pt) | Lipídios catiônicos à base de piperazina | |
| Xiao et al. | Protective role of isoflurane pretreatment in rats with focal cerebral ischemia and the underlying molecular mechanism | |
| BR112022015858A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometriose | |
| CY1124236T1 (el) | Διαλυμα εγχυσης λεβοντοπα | |
| MX2019013137A (es) | Metodos y composiciones para tratar enfermedades oculares alergicas. | |
| CO2023016081A2 (es) | Composición farmacéutica para prevenir o tratar una enfermedad cerebral y alimento funcional de salud para prevenir o aliviar una enfermedad cerebral que la comprende | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| BR112019007028A2 (pt) | métodos e composições farmacêuticas para o tratamento do câncer renal | |
| Hong et al. | Baseline putamen volume as a predictor of positive symptom reduction in patients at clinical high risk for psychosis: a preliminary study | |
| Ingberg et al. | Effects of high and low 17β-estradiol doses on focal cerebral ischemia in rats | |
| Saqib et al. | A comparison of efficacy of single topical permethrin and oral ivermectin in the treatment of scabies | |
| BR112023016319A2 (pt) | Anticorpos anti-beta amiloide e usos dos mesmos | |
| Gharedaghi et al. | Dinitrobenzene sulphonic acid-induced colitis impairs spatial recognition memory in mice: roles of N-methyl D-aspartate receptors and nitric oxide | |
| Lutz et al. | Do neurobiological differences exist between paranoid and non-paranoid schizophrenia? Findings from the bipolar schizophrenia network on intermediate phenotypes study | |
| Pelivan et al. | Vitamin B1, B6 and B12 injections relieve symptoms of burning mouth syndrome |